ReviewTranslational cancer research2026
The double-edged sword of tumor-targeted treatment: the influence of targeted therapy on the heart.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As an important means of modern cancer treatment, targeted therapy has significant efficacy, but cardiac toxicity cannot be ignored. From subclinical myocardial injury to severe heart failure (HF), it poses significant challenges to the long-term survival and quality of life of patients. This article summarizes the impact of targeted therapy drugs on cardiac function and their mechanisms, including cardiomyocyte damage, myocardial hypertrophy, and HF, and conducts in-depth research into potential molecular mechanisms. These include direct cardiomyocyte damage through targeted pathway inhibition [e.g., human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR)], and off-target effects that lead to oxidative stress, mitochondrial dysfunction, iron deposition, and immune-mediated damage (e.g., checkpoint inhibitors). While the review also outlines strategies for preventing and treating cardiac toxicity of targeted therapy, these include pre-treatment cardiovascular risk stratification, advanced imaging modalities [such as speckle tracking echocardiography and cardiac magnetic resonance imaging (MRI)], biomarker-based monitoring [such as high-sensitivity cardiac troponin (hs-cTn), B-type natriuretic peptide (BNP)/N-terminal pro B-type natriuretic peptide (NT-proBNP)], timely drug intervention, and strategic modification of cancer treatment plans. The main objective of the review is to elucidate and enhance clinical understanding of the cardiotoxicity associated with contemporary targeted anti-cancer therapies. By deepening their understanding of the different mechanisms and clinical manifestations of drug-induced heart injury, early detection, multidisciplinary collaboration, and personalized treatment decisions can be promoted. Ultimately, this approach aims to optimize cancer treatment outcomes while maintaining patients' overall quality of life and cardiovascular health.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.